United States News All stories

The Mosaic Company (NYSE:MOS) announced a significant restructuring of its Brazilian operations on April 8, 2026, confirming plans to idle and demobilize its Araxá Mining and Chemical Complex and halt related mining at Patrocínio.

Cango (NYSE:CANG), a global Bitcoin miner and energy infrastructure developer, announced its March 2026 operational update on April 8, detailing a strategic pivot toward a lean-production model that prioritizes cash margins over aggressive scale.

Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.

AtaiBeckley (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing next-generation mental health treatments, reported on April 8, 2026, peer-reviewed Phase 2a results demonstrating that a single intranasal dose of BPL-003 achieved rapid and sustained clinical benefits in patients with Treatment-Resistant Depression (TRD).

Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, reached a historic milestone on April 8, 2026, with the launch of Europe’s first commercial robotaxi service in Zagreb, Croatia.

ECARX Holdings (NASDAQ:ECX), a global leader in automotive intelligence technology, announced on April 8, 2026, that its Board of Directors has approved a preliminary plan to pursue the acquisition of a minority interest and specific intellectual property assets related to FlyMe OS.

Accenture (NYSE:ACN) has acquired Keepler Data Tech, a prominent Spanish cloud-native AI and data firm, in a strategic move to accelerate its ability to reinvent core business processes for global clients through advanced intelligence solutions.

United Microelectronics (NYSE:UMC), a leading global semiconductor foundry, reported on April 8, 2026, its unaudited net sales for March 2026, showing continued year-over-year gains in a stabilizing global chip market.

Mesoblast (NASDAQ:MESO) announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to proceed directly to a registrational trial for Ryoncil® (remestemcel-L) in children with Duchenne muscular dystrophy (DMD).

Shell (NYSE:SHEL) updated its first-quarter 2026 outlook on April 8, raising its indicative refining margin to $17 per barrel while warning that the ongoing conflict in the Middle East is driving increased uncertainty across its global operations.

Hemispherian, a clinical-stage oncology company, announced on April 8, 2026, the initiation of a Phase 1/2a clinical trial for its lead candidate, GLIX1, marking a significant milestone in the development of targeted therapies for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

CME Group (NYSE:CME) reported record international average daily volume for the first quarter of 2026, as global market participants ramped up hedging activity across interest rates and commodities amid a volatile start to the year.

Marsh McLennan Agency, a subsidiary of Marsh (NYSE:MRSH), announced on April 7, 2026, the acquisition of Seitz Insurance Agency, a prominent independent firm based in Sidney, Montana, specializing in high-growth regional sectors.

HEICO (NYSE:HEI) announced on April 7, 2026, that its Flight Support Group has acquired an 80% stake in Sherwood Avionics and Accessories, a prominent Florida-based provider of maintenance, repair, and overhaul (MRO) services.

GoPro (NASDAQ:GPRO) announced on April 7, 2026, that its Board of Directors has approved a comprehensive restructuring plan designed to significantly reduce operating costs and accelerate the company’s push toward stronger operating leverage.

Skillsoft (NYSE:SKIL), a global leader in corporate digital learning and skills management, reported its financial results for the fourth quarter and full fiscal year ended January 31, 2026, on April 7, 2026.

SolarMax Technology (NASDAQ:SMXT), a leading integrated solar energy company, announced record financial results for the fiscal year ended December 31, 2025, marked by a near-fourfold increase in revenue and a significant expansion of its energy storage pipeline.

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.

TransDigm Group (NYSE:TDG), a leading global designer, producer, and supplier of highly engineered aircraft components, announced on April 7, 2026, the successful completion of its acquisition of Jet Parts Engineering and Victor Sierra Aviation Holdings for approximately $2.2 billion in cash.

Savara (NASDAQ:SVRA), a clinical-stage biopharmaceutical company dedicated to rare respiratory diseases, announced on April 7, 2026, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI.

Fluor (NYSE:FLR) announced on April 7, 2026, that it has been selected by America First Refining (AFR) to execute the front-end engineering and design (FEED) for a landmark large-scale refining facility in Brownsville, Texas.

Gilead Sciences (NASDAQ:GILD) announced on April 7, 2026, that it has entered into a definitive agreement to acquire Tubulis GmbH, a private German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs).

Jaguar Health (NASDAQ:JAGX), a commercial-stage pharmaceutical company focused on gastrointestinal products, released its consolidated financial results for the fourth quarter and full year ended December 31, 2025, on April 7, 2026.

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).